Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results for ATNM-400 across ...
Stocktwits on MSN
CADL stock gets a bullish call just weeks before crucial prostate cancer data reveal
The firm stated that the stock is deeply undervalued, with a discounted cash flow estimate of around $30 per share. ・Investors are awaiting extended phase 3 data for CAN-2409 in prostate cancer, as ...
2d
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc.
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell ...
Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.
Morning Overview on MSN
Study maps prostate immune niches, finds T cells linger for months
Prostate cancer has long frustrated immunologists. Checkpoint inhibitors that unleash the immune system against tumors in the ...
Researchers have discovered that the immune system's T cells can travel to the prostate to provide long-term protection against infections. Their findings suggest we might harness these same ...
Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results